Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 2
2023 1
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?
Akdag G, Isik D, Dogan A, Yildirim S, Kinikoglu O, Topal A, Oksuz S, Turkoglu E, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: kinikoglu o. Medicina (Kaunas). 2024 Aug 22;60(8):1372. doi: 10.3390/medicina60081372. Medicina (Kaunas). 2024. PMID: 39202652 Free PMC article.
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients.
Yildirim S, Dogan A, Akdag G, Cavdar E, Kinikoglu O, Oksuz S, Yildiz HS, Kucukoz Uzun A, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: kinikoglu o. Cancers (Basel). 2024 Jul 11;16(14):2512. doi: 10.3390/cancers16142512. Cancers (Basel). 2024. PMID: 39061152 Free PMC article.
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Yildirim S, Dogan A, Akdag G, Yüksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Alan O, Coban Kokten S, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: kinikoglu o. Sci Rep. 2024 May 27;14(1):12123. doi: 10.1038/s41598-024-63096-7. Sci Rep. 2024. PMID: 38802494 Free PMC article.
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Akdag G, Yildirim S, Dogan A, Yuksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Turkoglu E, Alan O, Coban Kokten S, Isik D, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: kinikoglu o. Chemotherapy. 2024;69(3):141-149. doi: 10.1159/000537874. Epub 2024 Feb 16. Chemotherapy. 2024. PMID: 38368871
14 results